Edition:
India

GlaxoSmithKline PLC (GSK.L)

GSK.L on London Stock Exchange

1,524.40GBp
18 Apr 2019
Change (% chg)

-16.40 (-1.06%)
Prev Close
1,540.80
Open
1,526.80
Day's High
1,536.20
Day's Low
1,523.20
Volume
5,924,105
Avg. Vol
7,769,127
52-wk High
1,648.80
52-wk Low
1,395.80

Select another date:

Tue, Apr 9 2019

Photo

GSK wins U.S. nod for two-drug HIV combination

GlaxoSmithKline Plc's two-drug treatment for HIV infections won U.S. market approval on Monday, boosting the British drugmaker's growth prospects against competitor Gilead Sciences Inc.

GSK wins U.S. nod for two-drug HIV combination

GlaxoSmithKline Plc's two-drug treatment for HIV infections won U.S. market approval on Monday, boosting the British drugmaker's growth prospects against competitor Gilead Sciences Inc.

UPDATE 2-GSK wins U.S. nod for two-drug HIV combination

April 8 GlaxoSmithKline Plc's two-drug treatment for HIV infections won U.S. market approval on Monday, boosting the British drugmaker's growth prospects against competitor Gilead Sciences Inc.

U.S. FDA approves GSK's two-drug HIV treatment

April 8 The U.S. Food and Drug Administration said on Monday it had approved GlaxoSmithKline Plc's two-drug HIV treatment.

GSK reports positive data for experimental blood cancer drug

GlaxoSmithKline received a boost for its oncology research on Thursday, as it reported further positive data from a study of its experimental drug for blood cancer.

GSK reports positive data for experimental blood cancer drug

March 21 GlaxoSmithKline received a boost for its oncology research on Thursday, as it reported further positive data from a study of its experimental drug for blood cancer.

GSK reports positive data from trial of endometrial cancer drug

GlaxoSmithKline said on Tuesday a study testing its experimental drug dostarlimab in women with recurrent or advanced endometrial cancer showed promising results.

GSK reports positive data from trial of endometrial cancer drug

March 19 GlaxoSmithKline said on Tuesday a study testing its experimental drug dostarlimab in women with recurrent or advanced endometrial cancer showed promising results.

British fraud office abandons Rolls-Royce, GSK investigations

LONDON The UK's Serious Fraud Office (SFO) has abandoned two of its largest and longest investigations, into alleged bribery at aero engine maker Rolls-Royce and drugs maker GlaxoSmithKline, in a move described by one lawyer as "extraordinary".

UPDATE 2-British fraud office abandons Rolls-Royce, GSK investigations

LONDON, Feb 22 The UK's Serious Fraud Office (SFO) has abandoned two of its largest and longest investigations, into alleged bribery at aero engine maker Rolls-Royce and drugs maker GlaxoSmithKline, in a move described by one lawyer as "extraordinary".

Select another date: